The treatment landscape for psoriasis just shifted. The U.S. Food and Drug Administration (FDA) has approved Icotyde (icotrokinra), a first-of-its-kind oral medication for moderate-to-severe plaque psoriasis, offering a new option for the estimated 8 million Americans living with the condition. For many, the appeal lies in its delivery: a daily pill, rather than the injections currently dominating advanced psoriasis treatment. This approval marks a significant step forward, potentially broadening access to effective therapies and addressing a key barrier to care for those hesitant about needles.
Psoriasis is a chronic autoimmune disease that causes skin cells to multiply too quickly, resulting in thick, scaly patches. While topical treatments are often the first line of defense, many patients require more systemic therapies to manage their symptoms. Until now, those systemic options have largely been injectable biologic drugs. Icotyde distinguishes itself as the first oral medication in the interleukin-23 (IL-23) receptor antagonist class, a group of drugs known for their effectiveness. The approval was announced on Wednesday, March 18, 2026, by Johnson & Johnson, the manufacturer of Icotyde.
A New Approach to Targeting Inflammation
Icotyde works by specifically blocking the IL-23 receptor, a key player in the inflammatory processes that drive psoriasis. By interrupting this signaling pathway, the medication helps to clear skin and reduce the severity of the disease. “It’s the first in its class to be oral. That’s a big deal,” says Ife J. Rodney, MD, founding director of Eternal Dermatology + Aesthetics in Fulton, Maryland. Clinical trials demonstrated promising results, with approximately 70 percent of patients achieving clear or nearly-clear skin after 16 weeks of treatment, and 55 percent experiencing a 90 percent reduction in psoriasis severity, based on data from four phase 3 clinical trials involving 2,500 patients.
Expanding Treatment Options for a Wider Range of Patients
The convenience of a daily pill is a major advantage, according to dermatologists. “For the first time, we have a targeted oral therapy hitting the IL-23 pathway, which we know is one of the most effective mechanisms in this disease,” explains Adam Friedman, MD, a professor and chair of dermatology at GW Medical Faculty Associates. “Historically, that level of precision, and in turn, effectiveness, has been reserved for injectables, but now You can offer it in a pill.” This is particularly significant for patients who may be apprehensive about injections, representing an estimated 75% of those who don’t progress from topical treatments to more advanced therapies, according to Johnson & Johnson.
Icotyde isn’t the only oral option available for psoriasis; Otezla (apremilast) and Sotyktu (deucravacitinib) are also oral medications used to treat the condition. However, Icotyde’s targeted approach to the IL-23 pathway sets it apart. The medication has also been approved for use in patients as young as 12, offering a valuable treatment option for pediatric psoriasis, notes Cindy Wassef, MD, a dermatologist at Premier Health Associates in Randolph, New Jersey.
Safety and Efficacy Profile
In clinical trials, Icotyde demonstrated a favorable safety profile. Side effects were comparable to those experienced by patients taking a placebo, with no new safety concerns identified over 52 weeks of treatment. The most commonly reported side effects included headache, nausea, cough, fungal infection, and fatigue. Johnson & Johnson cautions that, like other medications that affect the immune system, Icotyde may increase the risk of infections.
While Icotyde requires a few weeks to exert its full effect, according to Joshua Zeichner, MD, director of cosmetic and clinical research at Mount Sinai Hospital in New York City, studies suggest that the benefits are both significant and long-lasting with continued use. Dr. Friedman adds that the approval process for Icotyde may also be less burdensome than for some injectable biologics, potentially streamlining access to treatment for patients. “The label also requires less rigorous, and often overkill, laboratory tests prior to starting, which can be a roadblock for some. Overall that means less time undertreated, faster control of disease, and ultimately better outcomes.”
What’s Next for Icotyde?
Despite the excitement surrounding Icotyde, one key piece of information remains unavailable: the price. Johnson & Johnson has not yet announced how much the medication will cost, which will undoubtedly be a crucial factor in its accessibility. The company has also not yet specified a date for when Icotyde will be available to patients. However, the FDA approval represents a major milestone, and dermatologists are optimistic about the potential of this new treatment option to improve the lives of people living with psoriasis.
As Johnson & Johnson prepares for launch, further details regarding pricing and availability are expected in the coming months. Patients and healthcare providers can stay updated on the latest information through the company’s official website.
Disclaimer: This article provides general medical information and should not be considered a substitute for professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment of any medical condition.
Have thoughts on this new treatment option? Share your comments below, and share this article with anyone who might find it helpful.
